Publication:
Safety and Efficacy of the FRED Jr Flow Re-Direction Endoluminal Device for Intracranial Aneurysms: Retrospective Multicenter Experience With Emphasis on Midterm Results

Simple item page
dc.contributor.authorBALTACIOĞLU, FEYYAZ
dc.contributor.authorsJesser, Jessica; Alberalar, Nilüfer D.; Kizilkilic, Osman; Saatci, Isil; Baltacioglu, Feyyaz; Özlük, Enes; Killer-Oberpfalzer, Monika; Vollherbst, Dominik F.; Islak, Civan; Cekirge, Saruhan H.; Bendszus, Martin; Möhlenbruch, Markus; Koçer, Naci
dc.date.accessioned2022-03-02T05:44:33Z
dc.date.available2022-03-02T05:44:33Z
dc.date.issued2021-10-01
dc.description.abstractBackground and Purpose: Flow diversion is increasingly used as an endovascular treatment for intracranial aneurysms. In this retrospective multicenter study, we analyzed the safety and efficacy of the treatment of intracranial, unruptured, or previously treated but recanalized aneurysms using Flow Re-Direction Endoluminal Device (FRED) Jr with emphasis on midterm results. Materials and Methods: Clinical and radiological records of 150 patients harboring 159 aneurysms treated with FRED Jr at six centers between October 2014 and February 2020 were reviewed and consecutively included. Clinical outcome was measured by using the modified Rankin Scale (mRS). Anatomical results were assessed according to the O'Kelly-Marotta (OKM) scale and the Cekirge-Saatci Classification (CSC) scale. Results: The overall complication rate was 24/159 (16%). Thrombotic-ischemic events occurred in 18/159 treatments (11%). These resulted in long-term neurological sequelae in two patients (1%) with worsening from pre-treatment mRS 0–2 and mRS 4 after treatment. Complete or near-complete occlusion of the treated aneurysm according to the OKM scale was reached in 54% (85/158) at 6-month, in 68% (90/133) at 1-year, and in 83% (77/93) at 2-year follow-up, respectively. The rates of narrowing or occlusion of a vessel branch originating from the treated aneurysm according to the CSC scale were 11% (12/108) at 6-month, 20% (17/87) at 1-year, and 23% (13/57) at 2-year follow-up, respectively, with all cases being asymptomatic. Conclusions: In this retrospective multicenter study, FRED Jr was safe and effective in the midterm occlusion of cerebral aneurysms. Most importantly, it was associated with a high rate of good clinical outcome.
dc.identifier.doi10.3389/fneur.2021.722183
dc.identifier.issn1664-2295
dc.identifier.pages722183
dc.identifier.urihttps://hdl.handle.net/11424/218811
dc.identifier.volume12
dc.language.isoeng
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fneur.2021.722183/full
dc.titleSafety and Efficacy of the FRED Jr Flow Re-Direction Endoluminal Device for Intracranial Aneurysms: Retrospective Multicenter Experience With Emphasis on Midterm Results
dc.title.alternativeSafety and Efficacy of the FRED Jr Flow Re-Direction Endoluminal Device for Intracranial Aneurysms
dc.typearticle
dspace.entity.typePublication
local.avesis.id3e980f13-2cfa-4eb7-9d05-707e8f1fe6d4
local.indexed.atSCOPUS
local.indexed.atPUBMED
relation.isAuthorOfPublication14b6381a-4f6e-4ff9-92f6-842a481bc163
relation.isAuthorOfPublication.latestForDiscovery14b6381a-4f6e-4ff9-92f6-842a481bc163

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Jesser et al. - 2021 - Safety and Efficacy of the FRED Jr Flow Re-Directi.pdf
Size:
581.58 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs